Paclitaxel- and platinum-based postoperative chemotherapy for primary fallopian tube carcinoma: A single institution experience

Oncology

Volumn 75, Issue 1-2, 2008, Pages 42-48

  Papadimitriou, Christos A ^a,b   Peitsidis, Panagiotis ^a   Bozas, George ^a   Grimani, Irene ^a   Vlahos, George ^a   Rodolakis, Alexandros ^a   Lianos, Evangelos ^a   Bamias, Aristotelis ^a   Lainakis, George ^a   Dimopoulos, Meletios A ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b NONE   (Greece)

Author keywords

Adjuvant chemotherapy; Fallopian tube cancer; Paclitaxel; Platinum

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MELPHALAN; MESNA; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE COURSE; DRUG MEGADOSE; FEMALE; HUMAN; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; POSTOPERATIVE CARE; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; UTERINE TUBE CARCINOMA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; PACLITAXEL; PLATINUM COMPOUNDS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 50049134937     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000151668     Document Type: Article

References (35)

1. Sedlis A: Primary carcinoma of the fallopian tube. Obstet Gynecol Surv 1961;16:209-226.
2. Woolas R, Jacobs I, Davies AP, et al: What is the true incidence of primary fallopian tube carcinoma? Int J Gynecol Cancer 1994;4:384-388.
3. Rosenblatt KA, Weiss NS, Schwartz SM: Incidence of malignant fallopian tube tumors. Gynecol Oncol 1989;35:236-239.
4. Rose P: Fallopian tube cancer; in Raghavan D, Brecher M, Johnson D, Meropol N, Moots P, Thigpen J (eds): Textbook of Uncommon Cancer, ed 2. Chichester, Wiley, 1999, pp 681-687.
5. Pectasides D, Pectasides E, Economopoulos T: Fallopian tube carcinoma: a review. Oncologist 2006;11:902-909.
6. Yoonessi M: Carcinoma of the fallopian tube. Obstet Gynecol Surv 1979;34:257-270.
7. Rosen A, Ausch C, Hafner E, et al: A 15-year overview of management and prognosis in primary fallopian tube carcinoma. Eur J Cancer 1998;34:1725-1729.
8. McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
9. Neijt JP, Engelholm SA, Tuxen MK, et al: Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 2000;18:3084-3092.
10. Piccart MJ, Bertelsen K, James K, et al: Randomized intergroup trial of cisplatin/paclitaxel versus cisplatin/cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000;92:699-708.
11. Du Bois A, Lück HJ, Meier W, et al: A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003;95:1320-1329.
12. Aravantinos G, Fountzilas G, Kosmidis P, et al: Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: long-term efficacy results. A Hellenic Cooperative Oncology Group (HeCOG) study. Ann Oncol 2005;16:1116-1122.
13. Du Bois A, Weber B, Rochon J, et al: Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. J Clin Oncol 2006;24:1127-1135.
14. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Nat Cancer Inst 2000;92:205-216.
15. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
16. Papadimitriou C, Dafni U, Anagnostopoulos A, et al: High-dose melphalan and autologous stem cell transplantation as consolidation treatment in patients with chemosensitive ovarian cancer: results of a single-institution randomized trial. Bone Marrow Transplant 2008;41:547-554. doi:10.1038/sj.
17. Papadimitriou CA, Kouroussis C, Moulopoulos LA, et al: Ifosfamide, paclitaxel and cisplatin first-line chemotherapy in advanced, suboptimally debulked epithelial ovarian cancer. Cancer 2001;92:1856-1863.
18. Stewart SL, Jennifer M, Wike JM, Foster SL, Michaud F: The incidence of primary fallopian tube cancer in the United States. Gynecol Oncol 2007;107:392-397.
19. Podratz KC, Podczaski ES, Gaffey TA, O'Brien PC, Schray MF, Malkasian GD Jr: Primary carcinoma of the fallopian tube. Am J Obstet Gynecol 1986;154:1319-1326.
20. Maxson WZ, Stehman FB, Ulbright TM, Sutton GP, Ehrlich CE: Primary carcinoma of the fallopian tube: evidence for activity of cisplatin combination therapy. Gynecol Oncol 1987;26:305-313.
21. Asmussen M, Kaern J, Kjoerstad K, Wright PB, Abeler V: Primary adenocarcinoma localized to the fallopian tubes: report on 33 cases. Gynecol Oncol 1988;30:183-186.
22. Hirai Y, Kaku S, Teshima H, et al: Clinical study of primary carcinoma of the fallopian tube: experience with 15 cases. Gynecol Oncol 1989;34:20-26.
23. Muntz HG, Tarraza HM, Granai CO, Fuller AF Jr: Primary adenocarcinoma of the fallopian tube. Eur J Gynaecol Oncol 1989;10:239-249.
24. Rose PG, Piver MS, Tsukada Y: Fallopian tube cancer. The Roswell Park experience. Cancer 1990;66:2661-2667.
25. McMurray EH, Jacobs AJ, Perez CA, Camel HM, Kao MS, Galakatos A: Carcinoma of the fallopian tube. Management and sites of failure. Cancer 1986;58:2070-2075.
26. Harrison CR, Averette HE, Jarrell MA, Penalver MA, Donato D, Sevin BU: Carcinoma of the fallopian tube: clinical management. Gynecol Oncol 1989;32:357-359.
27. Peters WA 3rd, Anderson WA, Hopkins MP: Results of chemotherapy in advanced carcinoma of the fallopian tube. Cancer 1989;63:836-838.
28. Barakat RR, Rubin SC, Saigo PE, Lewis JL Jr, Jones WB, Curtin JP: Second-look laparotomy in carcinoma of the fallopian tube. Obstet Gynecol 1993;82:748-751.
29. Pectasides D, Barbounis V, Sintila A, Varthalitis I, Dimitriadis M, Athanassiou A: Treatment of primary fallopian tube carcinoma with cisplatin-containing chemotherapy. Am J Clin Oncol 1994;17:68-71.
30. Gadducci A, Landoni F, Sartori E, et al: Analysis of treatment failures and survival of patients with fallopian tube carcinoma: a Cooperation Task Force (CTF) study. Gynecol Oncol 2001;81:150-159.
31. Gemignani ML, Hensley ML, Cohen R, Venkatraman E, Saigo PE, Barakat RR: Paclitaxel-based chemotherapy in carcinoma of the fallopian tube. Gynecol Oncol 2001;80:16-20.
32. Baekelandt M, Jorunn NA, Kristensen GB, Trope CG, Abeler VM: Carcinoma of the fallopian tube. Cancer 2000;89:2076-2084.
33. Moore KN, Moxley KM, Nickles Fader A, et al: Serous fallopian tube carcinoma: a retrospective, multi-institutional case-control comparison to serous adenocarcinoma of the ovary. Gynecol Oncol 2007;107:398-403.
34. Kosary C, Trimble EL: Treatment and survival for women with fallopian tube carcinoma: a population-based study. Gynecol Oncol 2002;86:190-191.
35. Rosen A, Klein M, Lahousen M, et al: Primary carcinoma of the fallopian tube - a retrospective analysis of 115 patients. Austrian Cooperative Study Group for Fallopian Tube Carcinoma. Br J Cancer 1993;68:605-609.